Abstract
Concentrations of circulating adipokines in non-obese polycystic ovary syndrome (PCOS) patients had been reported in many researches, however, these results were conflicting. The aim of this meta-analysis was to assess whether the levels of circulating adipokines were changed in non-obese PCOS. To identify eligible studies, literature research was performed in the database of PubMed, Embase, Web of Science without the restriction of region, publication or language. Of the total studies found, only 81 met the inclusion criteria. The meta-analysis showed that circulating levels of adiponectin [-0.95 (95% CI, −1.36 to −0.53)] decreased statistically in non-obese PCOS women. On the contrary, circulating levels of chemerin [1.13 (95% CI, 0.08 to 2.18)], leptin [0.47 (95% CI, 0.13 to 0.81)], resistin [0.45 (95% CI, 0.03 to 0.88)] and visfatin [1.38 (95% CI, 0.68 to 2.09)] increased significantly in non-obese PCOS females. Besides, there was no statistically significant change in the circulating levels of apelin [0.32 (95% CI, −1.34 to 1.99), irisin [1.01(95% CI, −0.68 to 2.70), omentin [-0.37(95% CI, −1.05 to 0.31)] and vaspin [0.09(95% CI, −0.14 to 0.32)] in non-obese PCOS patients. Scientific evidence suggested that the levels of circulating adipokines altered in non-obese PCOS patients compared with controls. Independent of the degree of obesity, the abnormal change of circulating adipokines levels might play an important role in the occurrence and development of PCOS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Wenzhou Municipal Science and Technology Bureau (Y20180271), and the Health and Family Planning Commission of Zhejiang Province (2019317125).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Wenzhou Medical University
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data, models, and code generated or used during the study appear in the submitted article
